Sanofi ：Riliprubart’s Phase III MOBILIZE Study (NCT06290128) to be Terminated
On June 10 local time, Sanofi announced the termination of the Phase III MOBILIZE study (NCT06290128) of Riliprubart in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP).
Riliprubart (SAR445088, BIVV020) is a humanized IgG4 monoclonal antibody that selectively inhibits activated C1 in the classical complement pathway of the innate immune system. By blocking C1, Riliprubart has the potential to suppress key inflammatory mechanisms driving demyelination and axonal damage in CIDP.
MOBILIZE was a Phase III, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Riliprubart in subjects with refractory chronic inflammatory demyelinating polyradiculoneuropathy.
Buy Riliprubart from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
